Burke Steven Keith 4

What Happened
Steven Keith Burke, SVP and Chief Medical Officer of Akebia Therapeutics (AKBA), disposed of a total of 67,658 shares on 2026-02-02 in three open-market sales at $1.39 per share, totaling roughly $94,045. The filing shows the sales were either made under a pre-arranged trading plan (Rule 10b5-1) or were automatic "sell-to-cover" transactions to satisfy tax withholding on vesting restricted stock units.

Key Details

• Transaction date and price: 2026-02-02, $1.39 per share.
  • 21,582 shares sold for $29,999
  • 25,375 shares sold for $35,271
  • 20,701 shares sold for $28,774
• Total shares sold: 67,658; approximate proceeds: $94,045.
• Shares owned after transaction: not reported in the supplied filing details.
• Footnotes:
  • F1 — One sale pursuant to a Rule 10b5-1 trading plan adopted Nov 17, 2023.
  • F2–F4 — Other sales were automatic issuer sell-to-cover transactions to cover tax withholding on vesting/settlement of one-third portions of RSUs granted Jan 31, 2023; Jan 31, 2024; and Jan 31, 2025.
• Filing: Report filed 2026-02-04 for transactions on 2026-02-02; appears to be timely (filed within standard Form 4 window).
• Transaction code: S = Sale; F = tax withholding/sell-to-cover.

Context
Sales executed under a Rule 10b5-1 plan and automatic sell-to-cover transactions for tax withholding are common and typically routine administrative actions rather than explicit signals about an insider’s view of the company. This filing is informational; it does not by itself indicate insider sentiment or future company performance.